Characteristic | OS | DFS | ||
---|---|---|---|---|
Hazard ratio [95% CI] | P | Hazard ratio [95% CI] | P | |
Univariate analysis | ||||
 GR methylation group |  | 0.006 |  | 0.035 |
  Both C and U unmethylated | 1 |  | 1 |  |
  C methylated | 0.524 [0.218–1.260] | 0.149 | 0.549 [0.286–1.054] | 0.072 |
  U methylated, no C methylation | 2.008 [1.140–3.537] | 0.016 | 1.407 [0.864–2.291] | 0.170 |
Multivariate analysis | ||||
 Age |  | 0.083 |  | 0.152 |
  ≤ 45 years | 1 |  | 1 |  |
  > 45 years | 1.624 [0.939–2.810] |  | 1.389 [0.886–2.178] |  |
 Stage (pathological) |  | 0.985 |  | 0.976 |
  I | 1 |  | 1 |  |
  II | 1.054 [0.167–6.672] | 0.955 | 0.901 [0.179–4.529] | 0.899 |
  III | 0.731 [0.005–107.941] | 0.902 | 0.653 [0.015–27.996] | 0.824 |
 Pathological T-stage |  | 0.542 |  | 0.558 |
  T1 | 1 |  | 1 |  |
  T2 | 1.448 [0.751–2.790] | 0.269 | 1.313 [0.788–2.189] | 0.296 |
  T3/T4 | 1.401 [0.015–129.717] | 0.884 | 1.830 [0.073–46.030] | 0.713 |
 Nodal status |  | 0.022 |  | 0.029 |
  Node negative | 1 |  | 1 |  |
  1–3 nodes | 1.052 [0.334–3.308] | 0.932 | 1.638 [0.540–4.972] | 0.383 |
  4–9 nodes | 1.153 [0.337–3.945] | 0.82 | 1.569 [0.488–5.048] | 0.45 |
  10+ nodes | 5.007 [1.201–20.875] | 0.027 | 6.004 [1.494–24.129] | 0.012 |
 Adjuvant chemotherapy |  | 0.517 |  | 0.624 |
  CEF | 1 |  | 1 |  |
  CMF | 1.018 [0.493–2.103] | 0.961 | 0.944 [0.519–1.718] | 0.851 |
  AC | 0.698 [0.319–1.526] | 0.367 | 0.755 [0.399–1.426] | 0.386 |
 Treatment |  | 0.552 |  | 0.136 |
  Placebo | 1 |  | 1 |  |
  Tamoxifen | 0.844 [0.484–1.474] |  | 0.710 [0.452–1.115] |  |
 GR methylation group |  | 0.006 |  | 0.041 |
  Both C and U unmethylated | 1 |  | 1 |  |
  C methylated | 0.504 [0.203–1.255] | 0.141 | 0.559 [0.280–1.115] | 0.099 |
  U methylated, no C methylation | 1.988 [1.112–3.553] | 0.02 | 1.431 [0.866–2.365] | 0.162 |